200 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
a draft label describing chronic and acute symptomatic benefit, in addition to acute reduction in ocular redness of reproxalap. The review period
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
filtration rate ("eGFR") total and chronic slope versus
irbesartan, narrowly missing statistical significance in eGFR total slope while achieving … statistical significance in eGFR chronic slope for purposes of regulatory review in the EU. All topline efficacy endpoints favored FILSPARI and patients
8-K
EX-99.1
ggqek5tbfq99 92et
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
l4ttxme
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
a51oj
8 Aug 22
Ligand Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
908nm40lq56g0 ksy
17 Feb 22
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
4:03pm
8-K
EX-99.1
lkdvy2n08a wu
3 Feb 21
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
7:45am
8-K
EX-99.1
0iexpcb fjn2kp
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
EX-99.1
f74uj9n1gj2dzxmbj
6 Feb 20
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
4:05pm